Session: SUN 839-872-Diabetes & Obesity Management
Poster Board SUN-858
Methods: Subgroup analysis as part of a cumulative, prospective, registry study of hypogonadal men with testosterone levels below 12.1 nmol/L. 71 men were obese and had T2D diagnosed and treated by their family practitioner. After diagnosis of hypogonadism in our urology practice, they received TU 1000 mg/12 weeks following an initial 6-week interval for up to five years. Data are available for 71 men for one year, 57 for two years, 49 for three years, 42 for four years and 32 for five years. Declining numbers do not reflect drop-outs but are a result of the registry design. New patients are consecutively entered once they have completed one year of treatment.
Results: At the end of the observation period, mean weight (kg) decreased from 117.07±11.66 (minimum 87.0, maximum 139.00) to 94.84±9.38 (min 80.0; max 114.0). This decrease was statistically significant vs baseline (p<0.0001) and each year compared to the previous year (p<0.0001). Mean change from baseline was 18.29±0.58 kg or 15.71±0.47%.
Waist circumference (cm) as a measure of abdominal fat decreased from 112.9±7.21 (min 89.00; max 129.00) to 101.72±7.29 (min 85.00; max 117.00), BMI from 37.75±3.51 (min 30.10; max 46.51) to 31.09±2.68 (min 25.88; max 35.98). These changes were also statistically significant vs baseline (p<0.0001) and each year compared to the previous year (p<0.0001).
At the end of each year, HbA1c was available for 37, 30, 25, 22 and 16 men, resp. At baseline, HbA1c was 8.33±0.78% (min 6.90; max 11.60), declining steadily and statistically significantly to 5.88±0.4%.
Fasting glucose decreased from 6.61±0.77 to 5.42±0.16 mmol/L (119.07±13.89 to 97.63±2.83 mg/dl).
Conclusions: Normalizing testosterone in obese hypogonadal men with T2D produced weight loss and marked reductions in HbA1c and fasting glucose. These improvements were progressive over the full 5 years of the study. It cannot be excluded that standard diabetes treatment was changed in some patients by their family practitioners. However, our findings are consistent with the recent literature and confirm that major benefits can be expected from correcting hypogonadism in men with T2D.
Disclosure: FS: Employee, Bayer Pharma AG. AH: Speaker, Bayer Pharma AG, Speaker, Takeda. GD: , Bayer Pharma AG. AMT: Investigator, Bayer Pharma AG.
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters